Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)Suresh S. Ramalingam, Claude El Kouri, Román Pérez-Soler et al.|Annals of Oncology|2013Cited by 57
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJoseph Gligorov, Luis Matamala, Beyhan Ataseven et al.|European Journal of Cancer|2017Cited by 47